Long-term analysis of children with metastatic neuroblastoma treated in the ENSG5 randomised clinical trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Long-term analysis of children with metastatic neuroblastoma treated in the ENSG5 randomised clinical trial

Published:2018-12-05 Issue:4 Volume:66 Page:e27565
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Moreno Lucas¹²³^ORCID,Vaidya Sucheta J.²,Schrey Dominik²,Pinkerton C. Ross⁴,Lewis Ian J.⁵,Kearns Pamela R.³,Machin David⁶,Pearson Andrew D. J.⁷,

Affiliation:

1. Clinical Trials Unit; Department of; Paediatric Haematology, Oncology and SCT; Hospital Infantil Universitario Niño Jesus; Madrid Spain

2. Children and Young People's Unit; The Royal Marsden NHS Foundation Trust; Sutton United Kingdom

3. Cancer Research UK Clinical Trials Unit; University of Birmingham; Birmingham United Kingdom

4. Hummingbird House Children's Hospice; Brisbane Australia

5. Leeds Community Healthcare NHS Trust; Leeds United Kingdom

6. Department of Cancer Studies; Clinical Sciences Building; Leicester Royal Infirmary; University of Leicester; Leicester United Kingdom

7. Children and Young People's Unit; The Royal Marsden NHS Foundation Trust; Sutton United Kingdom (retired)

Funder

Oak Foundation

National Institute for Health Research

Cancer Research UK

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology, and Child Health

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pbc.27565/fullpdf

Reference17 articles.

1. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial;Kreissman;Lancet Oncol,2013

2. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial;Pearson;Lancet Oncol,2008

3. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid;Matthay;N Engl J Med,1999

4. Busulphan-melphalan as a myeloablative therapy (MAT) for high-risk neuroblastoma: results from the HR-NBL1/SIOPEN trial;Ladenstein;J Clin Oncol,2011

5. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma;Yu;N Engl J Med,2010

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Two bullets in the gun: combining immunotherapy with chemotherapy to defeat neuroblastoma by targeting adrenergic-mesenchymal plasticity;Frontiers in Immunology;2023-10-02

2. Clinically relevant treatment of PDX models reveals patterns of neuroblastoma chemoresistance;Science Advances;2022-10-28

3. The impact of response to induction chemotherapy on the event-free and overall survival in patients with high-risk neuroblastoma: a systematic review and meta-analysis;Pediatric Hematology/Oncology and Immunopathology;2022-06-25

4. Enhancing sustained-release local therapy: Single versus dual chemotherapy for the treatment of neuroblastoma;Surgery;2020-06

5. Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR;Annals of Oncology;2020-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3